세계의 의약품 포장 시장(-2030년) : 원료(플라스틱, 종이 및 판지, 유리, 금속), 유형(플라스틱 병, 블리스터, 캡 및 클로저, 라벨 및 액세서리, 프리필드 실린지), 투여 경로, 지역별

The pharmaceutical packaging market is projected to reach USD 364.11 billion by 2030 from USD 174.85 billion in 2025, at a CAGR of 15.8% during the forecast period.

The pharmaceutical packaging market is witnessing significant growth opportunities, partly fueled by increasing demand for safe, reliable, and patient-centric packaging solutions across a variety of sectors, including hospitals, retail pharmacies, and e-pharmacies. Pharmaceutical packaging maintains the integrity of the product, stops it from becoming contaminated, and allows for convenient and safe delivery of the drug. In addition, as regulatory- and safety-motivated concerns mount, the US. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will push for greater requirements around materials, serialization, and anti-counterfeiting. Manufacturers of vehicles will begin increasing the conceptual development of good packaging systems, like those that are tamper-evident, child-resistant, and smart packaging. Safety, regulatory compliance, and packaging systems for children will push the industry to introduce digital and track-and-trace technologies, such as packaging enabled with RFID or QR codes. Pharmaceutical packaging will be moveable and influential in the ongoing evolution of investment in drug safety, product authenticity, and patient-specific features for a system of healthcare delivery in the future.

"By packaging type, primary packaging is projected to be the fastest-growing packaging type during the forecast period."

In the forecast period, primary packaging is projected to be the fastest-growing type of pharmaceutical packaging. This segment will grow because primary packaging is directly responsible for drug stability, sterility, and patient safety, particularly for more sensitive drugs, such as biologics and injectables. For example, the increasing demand for prefilled syringes, blister packs, vials, and ampoules indicates the manufacturing growth of pharmaceuticals and the desire for patients to have drugs packaged in more convenient formats ready for use. In addition, primary packaging is important in meeting regulatory challenges and serialization requirements. It also addresses concerns regarding tamper evidence and counterfeiting. Advances in barrier coatings, smart labels, and child-resistant closures will enhance functionality and product demand in global health care markets.

"By drug delivery, oral drugs are estimated to account for the second-largest market during the forecast period."

Oral drug delivery is estimated to account for the largest portion of the pharmaceutical packaging market in 2024 among the delivery methods for drug delivery systems. The packaging formats related to oral drug delivery are tablets, capsules, and oral liquids, primarily because of their convenience, affordability, and ability to promote adherence, or compliance, among patients. The packaging formats for oral solid doses will include blister packs and bottles, due to their portability, ability for unit dose, and ability to protect the dose from moisture and other contaminants. Increasing trend towards self-medication, in particular in the over-the-counter self-medication market, is also driving the demand for user-friendly oral drug delivery packaging. In addition, manufacturers continue to enhance oral drug packaging with sustainable aspects and easier access for older adults (e.g., easy-to-open and clearly labeled dosage designs).

"By raw material, paper & paperboard is set to account for the second-largest market share during the forecast period."

For the duration of the forecast period, paper & paperboard packaging is estimated to account for the second biggest market share in the pharmaceutical packaging market because this packaging type is mostly relevant to the secondary and tertiary packaging applications. The recyclable qualities of paper and paperboard materials, price advantage, and support for sustainability goals come to the forefront as pharmacy manufacturers respond to both societal and legislative pressures to limit plastic usage. The use of paperboard cartons, leaflets, and labels plays a key role in product identification, such as dose direction and legislative requirements for serialization and anti-counterfeiting, and tracking sustainability disposal practices. The sustainable focus on limited usage of plastics and overall desire to conform to the principles of a circular economy will continue to be drivers of the paper-based pharmaceutical packaging markets in developed regions, especially where sustainability initiatives are a priority.

"Asia Pacific is projected to account for the second-largest market share in the pharmaceutical packaging market during the forecast period."

In 2024, the Asia Pacific region accounted for the second largest share within the global pharmaceutical packaging market. The sustained strength of the region is principally based upon its growing pharmaceutical manufacturing base, particularly in emerging markets such as China, India, and Japan, which are prime markets for the development of generic and branded drug products. Growth in healthcare expenditures, a growing middle-class population, and improved access to healthcare services are increasing demand for pharmaceuticals, which is also driving demand for advanced pharmaceutical packaging offerings. This trend is also supported by an increase in chronic diseases and governmental policies aimed at establishing an effective domestic supply chain for medications, both for driving the need for safe and effective pharmaceutical packaging. The growth of contract manufacturing and pharmaceutical packaging services continues to expand in the Asia Pacific region, with attendant levels of investment from established companies, allowing these players to benefit from lower-cost production capabilities and scaled efficiencies. The combination of the previously outlined trends will substantiate the Asia Pacific region as a major contributor to the accelerated growth associated with the global pharmaceutical packaging market.

By Company Type: Tier 1: 25%, Tier 2: 42%, and Tier 3: 33%

By Designation: C-level Executives: 20%, Directors: 30%, and Other Designations: 50%

By Region: North America: 20%, Europe: 10%, Asia Pacific: 40%, South America: 10%, and Middle East & Africa: 20%

Notes: Other designations include sales, marketing, and product managers.

Tier 1: Greater than USD 1 Billion; Tier 2: Between USD 500 million and USD 1 Billion; and Tier 3: Less than USD 500 million

Companies Covered: Amcor PLC (Switzerland), Gerresheimer AG (Germany), Schott AG (Germany), Aptar Group, Inc. (US), BD (US), WestRock Company (US), NIPRO Corporation (Japan), Catalent Inc. (US), Sealed Air (US), and West Pharmaceutical Services (US) are covered in the report.

The study includes an in-depth competitive analysis of these key players in the pharmaceutical packaging market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the pharmaceutical packaging market based on type (plastic bottles, blister packs, caps & closures, prefilled syringes, pouches & strips, prefilled inhalers, vials, ampoules, cartridges, labels & accessories, medical specialty bags, temperature-controlled packaging, medication tubes, and jars & canisters), drug delivery (oral drugs, pulmonary, transdermal, injectables, topical, nasal, ocular/ophthalmic and iv drugs), packaging type (primary and secondary) by raw material (plastics, paper & paperboard, and glass, metal) and region (Asia Pacific, North America, Europe, South America, and Middle East & Africa). The report's scope covers detailed information regarding the drivers, restraints, challenges, and opportunities influencing the growth of the pharmaceutical packaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, and key strategies, such as partnerships, collaborations, mergers, acquisitions, product launches, and expansions, associated with the pharmaceutical packaging market. This report covers a competitive analysis of upcoming startups in the pharmaceutical packaging market ecosystem.

Reasons to Buy the Report

The report will offer the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall pharmaceutical packaging market and the subsegments. This report will help stakeholders understand the competitive landscape, gain more insights into positioning their businesses better, and plan suitable go-to-market strategies. The report will help stakeholders understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following points:

Assessing the major drivers (growing healthcare expenditure and pharmaceutical industry in emerging economies, increasing demand for drug delivery devices and blister packaging, and technological advancements contributing to the growth of pharmaceutical packaging), restraints (increasing overall packaging costs owing to dynamic regulatory policies and lack of access to proper healthcare), opportunities (growing demand for primary pharmaceutical packaging and expansion of personalized medicine), and challenges (safeguarding against counterfeit products and balancing innovations with cost efficiency).

Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product & service launches in the pharmaceutical packaging market.

Market Development: Comprehensive information about profitable markets - the report analyzes the pharmaceutical packaging market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the pharmaceutical packaging market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Amcor plc (Switzerland), Gerresheimer AG (Germany), Schott AG (Germany), Aptar Group, Inc. (US), BD (US), WestRock Company (US), NIPRO (Japan), Catalent Inc. (US), Sealed Air (US), and West Pharmaceutical Services (US), among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 UNITS CONSIDERED
    • 1.3.4.1 Currency/Value unit
    • 1.3.4.2 Volume unit
• 1.4 LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 GROWTH RATE FORECAST/ASSESSMENT
  • 2.5.1 SUPPLY SIDE
  • 2.5.2 DEMAND SIDE
• 2.6 RISK ASSESSMENT
• 2.7 LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL PACKAGING MARKET
• 4.2 PHARMACEUTICAL PACKAGING MARKET, BY RAW MATERIAL
• 4.3 PHARMACEUTICAL PACKAGING MARKET, BY TYPE
• 4.4 PHARMACEUTICAL PACKAGING MARKET, BY PACKAGING TYPE
• 4.5 PHARMACEUTICAL PACKAGING MARKET, BY DRUG DELIVERY
• 4.6 PHARMACEUTICAL PACKAGING MARKET, BY KEY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing healthcare expenditure and pharmaceutical industry in emerging economies
    • 5.2.1.2 Rising demand for drug delivery devices and blister packaging
    • 5.2.1.3 Technological advancements in pharmaceutical packaging
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Increase in overall packaging costs due to dynamic regulatory policies
    • 5.2.2.2 Lack of access to proper healthcare in emerging economies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for primary pharmaceutical packaging
    • 5.2.3.2 Growth in personalized medicine
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Safeguarding counterfeit products
    • 5.2.4.2 Balancing innovations with cost efficiency
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6.2 REGULATIONS
    • 5.6.2.1 21 CFR Part 211 - Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals (USA)
    • 5.6.2.2 Federal Anti-Tampering Act (USA, 1983)
    • 5.6.2.3 Fair Packaging and Labeling Act (FPLA, USA, 1967)
    • 5.6.2.4 Good Manufacturing Practices (GMP - WHO Guidelines)
    • 5.6.2.5 ISO 15378:2017 - Primary Packaging Materials for Medicinal Products
    • 5.6.2.6 European Pharmacopoeia (Ph. Eur.)
    • 5.6.2.7 United States Pharmacopeia (USP)
    • 5.6.2.8 Japanese Pharmacopoeia (JP)
    • 5.6.2.9 Regulation (EU) 2017/745 on Medical Devices (MDR - Europe)
    • 5.6.2.10 International Council for Harmonisation (ICH) Guidelines
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 392310)
  • 5.7.2 EXPORT SCENARIO (HS CODE 392310)
• 5.8 PRICING ANALYSIS
  • 5.8.1 INDICATIVE AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY RAW MATERIAL
  • 5.8.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Nanotechnology
    • 5.9.1.2 Packaging food biologics
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Smart packaging
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Anti-counterfeit technology
• 5.10 PATENT ANALYSIS
  • 5.10.1 INTRODUCTION
  • 5.10.2 LEGAL STATUS OF PATENTS
  • 5.10.3 JURISDICTION ANALYSIS
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 MOISTURE BARRIER TECHNOLOGY FOR BETTER DRUG DELIVERY
  • 5.11.2 CUSTOM TECHNOLOGY FOR BETTER BREATHING
  • 5.11.3 STREAMLINING OPERATIONS AND REDUCING COSTS THROUGH MD LOGISTICS
• 5.12 KEY CONFERENCES AND EVENTS
• 5.13 INVESTMENT AND FUNDING SCENARIO
• 5.14 IMPACT OF GEN AI/AI ON PHARMACEUTICAL PACKAGING MARKET
  • 5.14.1 INTRODUCTION
  • 5.14.2 AI-POWERED TRACKING AND BLOCKCHAIN INTEGRATION
  • 5.14.3 ENHANCING PHARMACEUTICAL SECURITY THROUGH AI
  • 5.14.4 SMART AND CONNECTED DRUG PACKAGING
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 THREAT OF NEW ENTRANTS
  • 5.15.2 THREAT OF SUBSTITUTES
  • 5.15.3 BARGAINING POWER OF BUYERS
  • 5.15.4 BARGAINING POWER OF SUPPLIERS
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 MACROECONOMIC ANALYSIS
  • 5.17.1 INTRODUCTION
  • 5.17.2 GDP TRENDS AND FORECASTS
• 5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL PACKAGING MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 IMPACT ON COUNTRY/REGION
    • 5.18.3.1 US
    • 5.18.3.2 Europe
    • 5.18.3.3 Asia Pacific
  • 5.18.4 IMPACT ON TYPES
    • 5.18.4.1 Plastic bottles
    • 5.18.4.2 Medication tubes
    • 5.18.4.3 Other types

6 PHARMACEUTICAL PACKAGING MARKET, BY PACKAGING TYPE

• 6.1 INTRODUCTION
• 6.2 PRIMARY
  • 6.2.1 INNOVATIVE PACKAGING SOLUTIONS FOR DRUG DELIVERY SYSTEMS TO DRIVE MARKET
• 6.3 SECONDARY
  • 6.3.1 RISE IN ADOPTION OF PREFILLED CONTAINERS AND DELIVERY DEVICES TO FUEL DEMAND

7 PHARMACEUTICAL PACKAGING MARKET, BY RAW MATERIAL

• 7.1 INTRODUCTION
• 7.2 PLASTIC
  • 7.2.1 EXCELLENT BARRIER PROPERTIES AND COST-EFFECTIVENESS TO DRIVE MARKET
  • 7.2.2 HIGH-DENSITY POLYETHYLENE
  • 7.2.3 POLYESTER
  • 7.2.4 POLYPROPYLENE
  • 7.2.5 LOW-DENSITY POLYETHYLENE
  • 7.2.6 POLYVINYL CHLORIDE
  • 7.2.7 CYCLIC OLEFIN COPOLYMER
  • 7.2.8 POLYETHYLENE TEREPHTHALATE
• 7.3 PAPER & PAPERBOARD
  • 7.3.1 INNOVATIONS IN SECONDARY PACKAGING TO PROPEL MARKET
• 7.4 GLASS
  • 7.4.1 CHEMICAL RESISTANCE AND EFFECTIVE PROTECTION TO BOOST MARKET
• 7.5 METAL
  • 7.5.1 INCREASE IN USE OF ALUMINUM FOR BLISTER PACKAGING TO DRIVE MARKET
• 7.6 OTHER RAW MATERIALS

8 PHARMACEUTICAL PACKAGING MARKET, BY DRUG DELIVERY

• 8.1 INTRODUCTION
• 8.2 ORAL
  • 8.2.1 ADOPTION OF NANOCARRIERS AND CYCLODEXTRINS TO FUEL MARKET
• 8.3 INJECTABLE 102 8.3.1 RISE IN USE OF BIOLOGICS TO BOOST MARKET
• 8.4 TOPICAL
  • 8.4.1 RISE IN PREVALENCE OF SKIN DISEASES TO BOOST DEMAND FOR TOPICAL DRUGS
• 8.5 OCULAR/OPHTHALMIC
  • 8.5.1 INCREASE IN PREVALENCE OF OPHTHALMIC DISEASES TO DRIVE MARKET
• 8.6 NASAL
  • 8.6.1 RAPID ABSORPTION AND QUICK ACTION TO FUEL DEMAND FOR NASAL DROPS
• 8.7 PULMONARY
  • 8.7.1 RISE IN CASES OF LUNG DISORDERS TO DRIVE MARKET
• 8.8 TRANSDERMAL
  • 8.8.1 RISE IN DEMAND FOR PAINLESS DRUG DELIVERY AND SELF-ADMINISTRATION OF DRUGS TO FUEL MARKET
• 8.9 INTRAVENOUS
  • 8.9.1 HIGH OCCURRENCE OF CHRONIC DISEASES TO DRIVE DEMAND
• 8.10 OTHER DRUG DELIVERY MODES

9 PHARMACEUTICAL PACKAGING MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 PLASTIC BOTTLES
  • 9.2.1 EXTENSIVE USE IN PACKAGING ORAL DRUGS TO DRIVE DEMAND
  • 9.2.2 STANDARD PLASTIC BOTTLES
  • 9.2.3 PLASTIC DISPENSING BOTTLES
  • 9.2.4 PLASTIC JARS
• 9.3 BLISTER PACKS
  • 9.3.1 ANTIMICROBIAL RESISTANCE AND TAMPER-EVIDENT FEATURES TO DRIVE MARKET
  • 9.3.2 COMPARTMENT PACKS
  • 9.3.3 WALLET PACKS
• 9.4 LABELS & ACCESSORIES
  • 9.4.1 STRINGENT GUIDELINES REGARDING DRUG INSTRUCTIONS TO DRIVE MARKET
  • 9.4.2 SELF-ADHESIVE
  • 9.4.3 DIE-CUT
  • 9.4.4 HOLOGRAPHIC STRIPS
  • 9.4.5 TAMPER-PROOF
  • 9.4.6 OTHER LABELS & ACCESSORIES
• 9.5 CAPS & CLOSURES
  • 9.5.1 DEMAND FOR CHILD-RESISTANT AND TAMPER-EVIDENT PACKAGING TO FUEL MARKET
• 9.6 MEDICAL SPECIALTY BAGS
  • 9.6.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE DEMAND
• 9.7 PREFILLED SYRINGES
  • 9.7.1 RISE IN NEED FOR HIGH-QUALITY DRUG DELIVERY SYSTEMS TO BOOST MARKET
• 9.8 TEMPERATURE-CONTROLLED PACKAGING
  • 9.8.1 RISE IN DEMAND FOR TEMPERATURE-SENSITIVE DRUGS AND VACCINES TO FUEL MARKET
• 9.9 POUCHES & STRIP PACKS
  • 9.9.1 RISE IN DEMAND FOR COST-EFFECTIVE SOLUTIONS TO DRIVE MARKET
• 9.10 AMPOULES
  • 9.10.1 GROWTH IN DEMAND FOR SMALL DOSAGE SOLUTIONS TO DRIVE MARKET
• 9.11 VIALS
  • 9.11.1 DEMAND FOR VIALS IN VACCINE PACKAGING TO DRIVE GROWTH
• 9.12 PREFILLED INHALERS
  • 9.12.1 HIGH DEMAND FOR CONVENIENT AND ECO-FRIENDLY PACKAGING TO DRIVE MARKET
  • 9.12.2 METERED DOSE INHALERS
  • 9.12.3 DRY POWDER INHALERS
• 9.13 MEDICATION TUBES
  • 9.13.1 INCREASE IN DEMAND IN CURING SKIN AILMENTS TO DRIVE MARKET
  • 9.13.2 COMPOSITE TUBES
  • 9.13.3 ALL-PLASTIC TUBES
  • 9.13.4 COLLAPSIBLE METAL TUBES
• 9.14 JARS & CANISTERS
  • 9.14.1 EFFECTIVE BARRIER PROPERTIES TO FUEL DEMAND FOR DESICCANT CANISTERS
• 9.15 CARTRIDGES
  • 9.15.1 INCREASED USE IN CHRONIC DISEASES TO DRIVE MARKET
• 9.16 OTHER TYPES

10 PHARMACEUTICAL PACKAGING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 Rapid technological advancements in pharmaceutical packaging to fuel growth
  • 10.2.2 CANADA
    • 10.2.2.1 Expansion of pharmaceutical industry and increase in consumption of pharmaceutical products to boost market
  • 10.2.3 MEXICO
    • 10.2.3.1 Increase in chronic diseases and presence of free-trade agreements to fuel demand for pharmaceutical products
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 Investment in innovations in biologics and sustainable materials, aligning with EU regulations on packaging waste reduction to drive market
  • 10.3.2 FRANCE
    • 10.3.2.1 High demand for generic drugs and investment in biotherapies to drive market
  • 10.3.3 ITALY
    • 10.3.3.1 Rise in exports of pharmaceuticals to boost market
  • 10.3.4 UK
    • 10.3.4.1 Innovations in drug manufacturing with reliable legal system and strong protection of intellectual property to drive market
  • 10.3.5 SPAIN
    • 10.3.5.1 High-quality, cost-effective manufacturing capabilities, well-established R&D facilities in healthcare sector to boost demand
  • 10.3.6 RUSSIA
    • 10.3.6.1 Government initiatives for domestic production of pharmaceuticals to fuel market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
    • 10.4.1.1 Increased investments in R&D of biologics and biosimilar drugs to drive market
  • 10.4.2 JAPAN
    • 10.4.2.1 Global leader in product innovation with sizeable aging population to drive demand for medications
  • 10.4.3 SOUTH KOREA
    • 10.4.3.1 Well-developed healthcare industry and presence of major pharmaceutical manufacturers to drive market
  • 10.4.4 INDIA
    • 10.4.4.1 Large domestic consumption and export of generic drugs to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Wide adoption of Medicare and PBS schemes to drive market
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 SOUTH AMERICA
  • 10.5.1 BRAZIL
    • 10.5.1.1 Large availability of required raw materials, cost-effective labor, and robust regulatory policies to boost market
  • 10.5.2 ARGENTINA
    • 10.5.2.1 Prevalence of noncommunicable diseases to boost market despite sharp economic deceleration, remediated by government stabilization measures
  • 10.5.3 REST OF SOUTH AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 SAUDI ARABIA
    • 10.6.1.1 More comprehensive access to healthcare services to fuel demand for pharmaceuticals
  • 10.6.2 UAE
    • 10.6.2.1 Increasing initiatives for domestic pharmaceutical production to drive market
  • 10.6.3 SOUTH AFRICA
    • 10.6.3.1 Gradual rise in generic drug use to drive market
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES
• 11.3 MARKET SHARE ANALYSIS
• 11.4 REVENUE ANALYSIS
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.5.1 COMPANY VALUATION
  • 11.5.2 FINANCIAL METRICS
• 11.6 PRODUCT/BRAND COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Regional Footprint
    • 11.7.5.3 Raw material footprint
    • 11.7.5.4 Type footprint
    • 11.7.5.5 Drug delivery footprint
    • 11.7.5.6 Packaging type footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startups/SMEs
    • 11.8.5.2 Competitive benchmarking of key startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 AMCOR PLC (INCLUDING BERRY GLOBAL)
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Solutions/Services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 GERRESHEIMER AG
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Solutions/Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 SCHOTT AG
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Solutions/Services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
      • 12.1.3.3.2 Deals
      • 12.1.3.3.3 Expansions
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 APTARGROUP, INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Solutions/Services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 BD
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Solutions/Services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 WESTROCK COMPANY
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Solutions/Services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
    • 12.1.6.4 MnM view
  • 12.1.7 NIPRO
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Solutions/Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
    • 12.1.7.4 MnM view
  • 12.1.8 CATALENT, INC
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Solutions/Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
      • 12.1.8.3.2 Expansions
    • 12.1.8.4 MnM view
  • 12.1.9 SEALED AIR
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Solutions/Services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
    • 12.1.9.4 MnM view
  • 12.1.10 WEST PHARMACEUTICAL SERVICES, INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Solutions/Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches
      • 12.1.10.3.2 Deals
      • 12.1.10.3.3 Expansions
    • 12.1.10.4 MnM view
• 12.2 OTHER PLAYERS
  • 12.2.1 ALPLA
  • 12.2.2 ARDAGH GROUP S.A.
  • 12.2.3 CCL INDUSTRIES INC.
  • 12.2.4 FRANK NOE
  • 12.2.5 GAPLAST GMBH
  • 12.2.6 LONZA
  • 12.2.7 MONDI
  • 12.2.8 NOLATO AB
  • 12.2.9 ORIGIN PHARMA PACKAGING
  • 12.2.10 COMAR
  • 12.2.11 BILCARE LIMITED
  • 12.2.12 SGD PHARMA
  • 12.2.13 SILGAN PLASTICS
  • 12.2.14 VETTER PHARMA INTERNATIONAL GMBH
  • 12.2.15 SVAM TOYAL PACKAGING INDUSTRIES PVT. LTD.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS